Multinational medical giant Becton, Dickinson and Company (BD) has participated in the CIIE since 2020 and served as the chair of the medical equipment special committee of the CIIE Enterprise Alliance.

BD had helped set up an innovation incubation section in the medical equipment and healthcare products exhibition area of the CIIE in 2021. This section brought together industry, capital, and policy parties to help global medical technology innovation companies take root in China.

Reporter: BD has been the chair of the committee for three years. How would you evaluate the work of the committee?

BD: The committee has played a key role in promoting industry resource aggregation, industrial innovation and open cooperation.

The committee has also helped introduce advanced foreign technologies and helped them become integrated with the local market.

In the future, the committee will focus on introducing advanced small and micro-sized enterprises and boost their exchanges and cooperation with local enterprises.

Reporter: How will the committee assist in nurturing projects showcased in the innovation incubation section?

BD: As these innovative projects are still in their incubation phase, the committee will assist them in gaining a better understanding of China's regulations, market dynamics, and entry requirements. We will facilitate their connection with investors. The committee will also leverage the CIIE to expand the network and ecosystem of the entire industry in terms of innovation and entrepreneurship.

Reporter: BD has been making frequent investment moves in China. What do these actions signify?

BD: BD has witnessed China's rapid development since entering the Chinese market in 1994. It has been a firsthand participant and beneficiary of China's reform, opening-up, and high-quality development.

We maintain a steadfast confidence in China's continued development, and BD's ongoing investments in the Chinese market are a testament to our faith in China.

Reporter: Where does BD's confidence in the Chinese market come from?

BD: As a deeply involved participant in the industry, we believe that the Chinese medical device sector has shown a significant level of openness. This is evident not only in the innovative development of Chinese medical technology companies but also in the increasing enthusiasm of foreign medical technology companies for introducing investments and innovative technologies.

Reforms in the regulatory system have been instrumental in reducing the time it takes to introduce overseas high-quality innovative products. Thanks to the efficient regulatory process, BD has several innovative products that have gained approval for market entry in China with simply overseas clinical data.

By Zhao Guangmei